# Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Source: https://onco.cc/trials/nct05438420/  
OnCo record `nct05438420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in cervical cancer, run by Qurient Co., Ltd., active and no longer recruiting.

## Summary

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05438420 by Qurient Co., Ltd., with 120 participants planned, started 2023-01-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: Q702, Pembrolizumab. Conditions listed: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05438420
- Phase: 1/2
- Setting: A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors
- Sponsor: Qurient Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05438420: https://clinicaltrials.gov/study/NCT05438420

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05438420.json